Personalized cell therapy takes on advanced cancers in early trial
NCT ID NCT07482319
First seen Mar 25, 2026 · Last updated Jun 22, 2026 · Updated 11 times
Summary
This early-stage trial tests a new cell therapy called GK01 in 15 people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses the patient's own immune cells, which are trained in a lab to attack cancer cells. The main goals are to find the safest dose and check for side effects, with some early looks at whether the tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GK01 cell injection (patient's own immune cells trained to attack tumors)
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 15 participants, so it is primarily testing safety and dosing. The treatment may not shrink tumors or improve survival, and there are risks of side effects from the cell infusion.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.